ABSTRACT: Transcatheter aortic valve replacement (TAVR) has become a well-accepted option for treating patients with aortic stenosis at intermediate to high or prohibitive surgical risk. TAVR-related conduction disturbances, mainly new-onset left bundle-branch block and advanced atrioventricular block requiring permanent pacemaker implantation, remain the most common complication of this procedure. Furthermore, improvements in TAVR technology, akin to the increasing experience of operators/centers, have translated to a major reduction in periprocedural complications, yet the incidence of conduction disturbances has remained relatively high, with perhaps an increasing trend over time. Several factors have been associated with a heightened risk of conduction disturbances and permanent pacemaker implantation after TAVR, with prior right bundle-branch block and transcatheter valve type and implantation depth being the most commonly reported. New-onset left bundle-branch block and the need for permanent pacemaker implantation may have a significant detrimental association with patients' prognosis. Consequently, strategies intended to reduce the risk and to improve the management of such complications are of paramount importance, particularly in an era when TAVR expansion toward treating lower-risk patients is considered inevitable. In this article, we review the available evidence on the incidence, predictive factors, and clinical association of conduction disturbances after TAVR and propose a strategy for the management of these complications.
T he advent of transcatheter aortic valve replacement (TAVR) represents a paradigm shift for treating patients with severe symptomatic aortic stenosis who are at high or prohibitive surgical risk. [1] [2] [3] The rate of periprocedural complications has decreased over time, 4, 5 and TAVR has been increasingly performed with a minimalist approach, 6 evolving into a safe and "routine practice" procedure with predictable outcomes. This provided the rationale for an extension of TAVR indications to treating individuals at lower surgical risk. 7, 8 However, unlike other procedural complications, the incidence of conduction disturbances (ie, high-degree atrioventricular block [HAVB] requiring permanent pacemaker implantation [PPM] and new-onset left bundle-branch block [LBBB] ) has failed to decrease in recent times, with reports suggesting an increased risk associated with the use of some newer-generation transcatheter valves. [9] [10] [11] [12] [13] [14] Although the clinical consequences of new-onset LBBB and PPM after TAVR remain the subject of ongoing debate, the deleterious effects of conduction disturbances and a decrease in left ventricular function induced by a right ventriclebased paced rhythm are supported by solid evidence in other clinical settings. [15] [16] [17] [18] These findings highlight the paramount importance of limiting such TAVR-related complications because TAVR is set to expand to patients at intermediate and low surgical risk among whom the detrimental consequences of conduction disturbances and long-term right ventricular pacing may be even more pronounced. 19 This review aims to summarize the current evidence for the incidence, mechanisms, predictors, clinical associations, and management of conduction disturbances after TAVR.
THE CONDUCTION SYSTEM: UNDERSTANDING THE MECHANISMS OF CONDUCTION DISTURBANCES IN TAVR
The close proximity between the aortic valve and the conduction system explains the genesis of periprocedural conduction disturbances during TAVR ( Figure I in the online-only Data Supplement). Within the right atrium, the atrioventricular node lies within the triangle of Koch, which is delineated by the tendon of Todaro, the orifice of the coronary sinus, and the insertion point of the tricuspid valve septal leaflet. [20] [21] [22] The convergence of the tendon of Todaro and the septal attachment of the tricuspid valve on the atrioventricular component of the membranous septum forms the apex of the triangle, with the coronary sinus ostium forming its base. The atrioventricular node is located just inferior to the apex. The atrioventricular node continues as the bundle of His, piercing the membranous septum and penetrating to the left through the central fibrous body. On the left side, the conduction system exits immediately beneath the membranous septum and is positioned superficially on the crest of the interventricular septum, where it gives rise to the left bundle branch. The left bundle branch is intimately related to the base of the interleaflet triangle separating the noncoronary and right coronary leaflets of the aortic valve. This close relationship is the key to understanding conduction disturbances after TAVR. In the setting of TAVR, conduction disturbances result primarily from a direct mechanical insult to the conduction system associated with various degrees of edema, hematoma, and ischemia, as demonstrated by necropsy studies. 23 Of particular importance, however, is the great interindividual variability of the anteroposterior relationship of the atrioventricular node with respect to the apex of the triangle of Koch, as well as the length of the nonpenetrating (the most proximal part traversing the membranous septum) portion of the His bundle. These anatomic variations have been exquisitely demonstrated by Kawashima and Sato 24 in an autopsy series of 115 elderly patients. They described 3 major variants, with 50% of individuals exhibiting a relatively right-sided atrioventricular bundle and 30% with a left-sided atrioventricular bundle, whereas in ≈20% of patients, the bundle coursed under the membranous septum just below the endocardium. The last 2 above-described variants may expose patients to a higher risk of TAVR-induced conduction disturbances, especially patients with a short membranous septum. 25 Apart from the mechanical interaction between the transcatheter valve and the conduction system, there is evidence supporting the association between aortic stenosis and conduction disturbances. Several mechanisms have been proposed to explain this association:
calcium deposition on the conduction system as a result of its proximity to the aortic valve complex 26 and the development of left ventricular dysfunction, both of which have been associated with the occurrence of LBBB and advanced AVB in patients with aortic stenosis. 27 Urena et al 28 showed, in a study including 435 consecutive TAVR candidates who had 24-hour electrocardiographic monitoring the day before the procedure, that 3.5% of patients had episodes of advanced AVB or LBBB.
NEW-ONSET LBBB Incidence
New-onset LBBB after TAVR has been reported with a varying incidence across studies. This may reflect the inclusion of transient LBBB in some studies, discrepancies in the timing of measurement (ie, at hospital discharge or at 30-day follow-up), and differences in the type of transcatheter valve from 1 study to another. New-onset LBBB has been reported in about one fourth (4%-65%) of TAVR procedures with firstgeneration valves ( Figure 1A) . 9, 22, The occurrence of new-onset LBBB has been more frequent when the self-expandable CoreValve system (Medtronic Inc, Minneapolis, MN) is used, with rates ranging from 18% to 65% compared with 4% to 30% reported with the use of the balloon-expandable Edwards SAPIEN/SAPIEN XT valve (Edwards Lifesciences LLC, Irvine, CA) 22 ( Figure 1A) . Data on the occurrence of new-onset LBBB after TAVR with newer-generation devices remain scarce ( Figure 1B) . 9, 10, [58] [59] [60] [61] [62] [63] LBBB rates of 12% to 22% have been reported after implantation of the Edwards SAPIEN 3 valve. 9, 10, 58, 59 Similar findings were reported with the self-expandable Portico TAVR system (St. Jude Medical, St. Paul, MN), which does not have a flared inflow and has the theoretical advantage of being partially resheathable and repositionable. 62 However, these rates were considerably higher (55% and 77%) in 2 studies reporting outcomes with the mechanically expanded Lotus valve (Boston Scientific, Natick, MA), which also allows subtle changes in valve position after a suboptimal initial deployment.
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Timing and Evolution of LBBB After TAVR
In the TAVR setting, most conduction disturbances occur in the acute period (periprocedural or within 24 hours of the procedure). 64, 65 Although most events occur during valve expansion, new-onset LBBB may actually occur before valve implantation, mainly during guidewire insertion and balloon predilation. 66 New-onset LBBB appears in the periprocedural period in 85% to 94% of cases and persists at discharge or 30 days in ≈55% of cases (range, 44% to 65%). 37, 40, 41, 47, 50, 67 A small proportion of patients (2%-8.6% of cases, representing 6.6%-17.8% of new-onset LBBB) develop subacute LBBB (ie, from >24 hours after TAVR to discharge). 37, 47, 50 Late resolution of new-onset LBBB beyond discharge or at 30 days seems unlikely, 40, 50 considering that the reported rates of persistent new-onset LBBB at 1-year follow-up have been on the order of 60%. 37, 40 Likewise, late appearance of LBBB, from discharge to 1 year after TAVR, is a rare phenomenon, described in 0% to 2.9% of patients. 37, 40, 47, 50 Before hospital discharge, persistency of LBBB seems more likely among self-expandable CoreValve recipients (47.5%-72.5%) compared with their balloon-expandable Edwards counterparts (27.1%-43.6%). 34, 37 PPM rates of 5% to 14% have been reported at follow-up among patients with new-onset LBBB, 32, 37, 40, 41, 50 with the progression toward HAVB being the most frequent indication for PPM across studies. However, Nazif et al 40 reported an equal 47% rate of HAVB and sick sinus syndrome as the primary indications for PPM in balloon-expandable valve recipients with new-onset LBBB after the procedure.
Predictors
The main patient and procedural factors associated with new-onset LBBB after TAVR are summarized in Table 1 and presented more exhaustively in Table I in the online-only Data Supplement. Clinical risk factors of new-onset LBBB after TAVR include the presence of preprocedural conduction abnormalities, 46 especially prolonged QRS duration, 47 female sex, previous coronary artery bypass graft, 34 diabetes mellitus, 35 and the amount of calcification of the aortic valve. 46 Considering procedural characteristics associated with the occurrence of LBBB, the most consistently reported is the prosthesis implantation depth within the left ventricular outflow tract (LVOT). 33, 44, 45, 47, 68 The CoreValve prosthesis, which is progressively deployed from its ventricular side exerting high radial forces in the LVOT (often deeper than balloon-expandable valves), has been frequently identified as a predictor of newonset LBBB. 32, [34] [35] [36] Besides, several studies suggest that maneuvers associated with an overstretching/ overexpansion of the LVOT such as balloon predilation or implantation of large prosthesis in a smaller LVOT increase the risk of TAVR-induced LBBB. 41, 42, 44, 46, 68 The role of balloon predilation has been described as a first injury inflicted to the conduction system that is insufficient to generate a persistent and complete AVB but promotes its occurrence after a second injury represented by the valve implantation. 69 Patients' characteristics underlying the appearance of conduction disturbances may differ according to valve type. Indeed, it has been demonstrated that the degree of radial forces exerted on the LVOT, and consequently the conduction system, depends primarily on LVOT diameter for the self-expandable CoreValve, whereas it is associated with the geometry and stiffness (calcifications) of the host tissue for the balloon-expandable Edwards valves. 2 =32%) when data from 5 studies (3554 patients) were combined. This relationship may be explained by a specific association between new-onset LBBB, especially when the QRS duration is >160 milliseconds, and the risk of sudden cardiac death during follow-up, as demonstrated by Urena et al. 30, 39 This suggests that constant compression of the conduction system by the transcatheter valve may induce the progression of LBBB to HAVB ( Figure 2 ). Other pathophysiological mechanisms underlying this increased cardiac mortality risk include the risk of ventricular arrhythmias in patients with reduced ejection fraction and ventricular dyssynchrony and the evolution toward systolic dysfunction and terminal heart failure, 71 given that new-onset LBBB has been associated with a decreased recovery of left ventricular ejection fraction and a less favorable left ventricular remodeling after TAVR. 40, 41, 52 QRS duration at discharge may influence the clinical outcomes of new-onset LBBB, as evidenced by Meguro et al, 72 who demonstrated a higher all-cause mortality and rehospitalization for heart failure among patients with a QRS duration >150 milliseconds at discharge.
Few studies evaluated the association of new-onset LBBB with the risk of HAVB or PPM at follow-up after TAVR (Table III in the online-only Data Supplement). Approximately 13% of patients with new-onset LBBB developed HAVB in a study including 45% self-expandable valves recipients, 73 whereas 8% of patients implanted with a balloon-expandable valve presenting LBBB after TAVR eventually required PPM during the index hospitalization in the PARTNER program (Placement of Aortic Transcatheter Valves). 40 In univariable analyses, LBBB has consistently been associated with a higher 30-day risk of PPM, whereas its effect from 30 days to 1 year after TAVR has varied from 1 study to another. 34, 40, 41, 50, 51 However, 2 studies of similar sample size had conflicting conclusions about the independent association of LBBB with the risk of PPM (Table III in the online-only   Data Supplement) . 34, 41 This observation may reflect a lower threshold for treating patients with new-onset LBBB because HAVB was the indication for PPM in 47% to 95% of patients across studies. 40, 50 However, data from 2 recent meta-analyses suggest an ≈2-fold higher risk of PPM among patients with new-onset LBBB. Figure 3A 1,2,7,39,48,75-102 summarizes the incidence of PPM associated with TAVR using first-generation devices, including the main national or multicenter registries and randomized clinical trials. The rates of PPM after TAVR varied from 2% to 51% in 41 studies included in a recent meta-analysis, 103 and PPM was the most common TAVR complication, with a pooled rate of 13% in an analysis summarizing 49 studies encompassing 16 063 patients. 104 Similar to LBBB, PPM was 5 times more frequent among self-expandable CoreValve recipients (25%-28%) compared with patients who received a balloon-expandable Edwards SAPIEN/SAPIEN XT valve (5%-7%). 65, 103, 104 This increased risk of PPM with the CoreValve system was confirmed in the CHOICE randomized trial (Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis; 37.6% versus 17.3%; P<0.001). 92 The recent adoption of newer iterations of transcatheter aortic valves and delivery systems has led to a major decrease in major periprocedural complications. Nonetheless, the available evidence to date does not support a reduction in PPM rates since the arrival of newer-generation devices (Figure 3B ) [9] [10] [11] [12] [13] [14] 43, [58] [59] [60] [61] [62] [63] 96, 98, (CoreValve Evolut R FOR-WARD Study, S. Windecker, MD, PhD, unpublished data, 2016), suggesting that the improved repositioning/retrievability capabilities and antiparavalvular leak properties of the majority of these newer valves have little or no influence on the occurrence of conduction disturbances after TAVR. PPM rates >10% (11%-14%) have been reported in multicenter registries using the Edwards SAPIEN 3 valve, 107, 108, 110 which is as much as twice the PPM rate observed with the prior-generation balloon-expandable Edwards valves. Some groups have suggested that the increased risk of PPM with the SAPIEN 3 valve relates to a device-specific implantation technique and could be mitigated by a higher valve positioning (<25% of ventricular portion). 9, 111 Whether the adoption of such a technique in routine clinical practice can achieve PPM rates comparable to those of the SAPIEN/SAPIEN XT valves without compromising safety (valve migration/embolization, periprosthetic aortic regurgitation) remains to be proven. Of note, except for the Portico system with a nonflared annular section and a low valve placement within the stent that allow sealing without deep implantation in the LVOT, 62 no additional features have been specifically designed to address the risk of conduction disturbances. Significant reductions in such complications after TAVR are therefore unlikely in the foreseeable future.
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PPM AFTER TAVR Incidence
Two additional points should be considered with respect to the incidence of PPM after TAVR. First, patients with a prior pacemaker, although not being exposed to the risk of a new PPM after TAVR, were included in the denominator (ie, as patients without new PPM) in the calculation of PPM rates in most studies, resulting in a systematic underestimation of the real incidence of PPM after TAVR. 142 Second, the indications for PPM may have varied according to operator/center criteria, not always following current guidelines. As an example, some teams undertook prophylactic PPM in patients with new-onset LBBB after TAVR, which in turn resulted in an increased rate of PPM after TAVR. Moreover, the ongoing quest for shorter postprocedural hospital stay 143 is another factor that may have incited teams to proceed earlier with PPM, thus shortening the guidelinerecommended period of clinical observation after TAVR for evaluating the permanent versus transient behavior of conduction disturbances. 144 A reduction in PPM rates has been observed with a strict adherence to Class I and II indications as recommended by clinical guidelines. 67, 144 Timing and Evolution of HAVB After TAVR Like new-onset LBBB, TAVR-induced HAVB occurs mainly in the periprocedural setting; 60% to 96% of these events were recorded within 24 hours of TAVR with both balloon-and self-expandable valves. 73, 145, 146 Delayed HAVB has been inconsistently defined as occurring after the procedure or >24 hours after valve implantation. Approximately 2% to 7% of patients (representing up to 30% of all patients with HAVB) experienced delayed HAVB ≥48 hours after TAVR 73, 147 (A. Kagase, MD, unpublished data, 2016). Of note, in an analysis of 1064 patients undergoing TAVR, the implantation of a self-expandable prosthesis was not an independent predictor of delayed (ie, nonprocedural) HAVB. 73 Consistent with the timing of HAVB, PPM is mainly performed within 7 days of the procedure (85%-90% of cases), 65, 148 with a median time from TAVR to PPM of 3 days in the recent report from the Society of Thoracic Surgeons Transcatheter Valve Therapy registry. 75 Data on very late development of HAVB among patients without conduction disturbances at hospital discharge are scarce; however, this seems to be an uncommon phenomenon. Indeed, Toggweiler et al 73 demonstrated that patients with a normal ECG after TAVR (ie, sinus rhythm, no first-degree AVB, and no LBBB) did not experience delayed HAVB up to 8 days after TAVR, which suggests an exceedingly low risk of very late conduction disturbances among this subgroup. Similarly, Urena et al 41 reported a 99.6% 1-year survival free from PPM for HAVB among patients without new-onset LBBB at hospital discharge compared with 89.1% among their new-onset LBBB counterparts.
Like LBBB, TAVR-induced HAVB may resolve over time. Defining recovered HAVB as a transient block without the need for PPM or as a ventricular pacing rate <1% at 30 days, Kagase et al demonstrated an overall recovery rate of 48% in a registry including Edwards SAPIEN XT recipients, including 5 of 30 patients (17%) with PPM with a ventricular pacing rate <1% (A. Kagase, MD, unpublished data, 2016). This recovery rate was 59% for acute HAVB compared with 25% for delayed HAVB (P=0.025). The recovery pattern also differed between acute and delayed HAVB, with a more rapid recovery in those patients presenting with acute HAVB (within 24 hours versus ≥6 days). Several studies have provided insights into the fate of these conduction disturbances by performing systematic interrogations of the implanted pacemakers. 67, 68, [149] [150] [151] [152] [153] [154] [155] Although heterogeneity in defining pacemaker dependency and in the timing of pacemaker interrogation must be acknowledged, these studies provide further evidence that a significant proportion of conduction disturbances resolve during the follow-up period. Thus, overall pacemaker dependency rates after TAVR ranged from 27% to 68%, 150, 151 and rates of intrinsic atrioventricular conduction increased from 25.9% at 7 days to 59.3% at 30 days even among patients with a guideline Class I/II indication for PPM after TAVR. 67 However, some patients not classified as pacemaker dependent had high (>10%-20%) ventricular pacing rates in these studies. 151, 154, 155 Interestingly, Ramazzina et al 153 showed that pacemaker dependency may depend on the initial indication for the pacemaker because at the 12-month follow-up none of the 17 patients who received a prophylactic PPM for new-onset LBBB with or without first-degree AVB had a pacing rate >1% compared with 83% of pacemaker-dependent patients among those who underwent PPM for HAVB. These observations may have important clinical implications in the management of conduction disturbances after TAVR. However, it should be emphasized that the definition of pacemaker dependency needs to be consistent and may currently be inappropriate because even a <1% ventricular pacing rate may be due to paroxysmal HAVB and would therefore be enough to avoid sudden cardiac death. Only pacemakers allowing the detection of HAVB episodes, which should be carefully programmed to preserve native conduction, may identify true pacemaker dependency after TAVR.
Predictors of Need for PPM After TAVR
Several studies have evaluated factors predicting the need for PPM after TAVR (Table 2  and Table IV in the online-only Data Supplement) . 10, 34, 42, 44, 45, 51, 55, 61, 68, 69, 75, 87, 91, 111, 122, 145, 146, 148, 153, [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] In a recent meta-analysis of 41 studies including 11 210 TAVR recipients, Siontis et al 103 identified male sex, firstdegree AVB, left anterior hemiblock, and right bundlebranch block (RBBB) as preprocedural predictors of PPM, whereas the presence of intraoperative heart block and the use of a self-expandable prosthesis were the procedural predictors. In that study, the implantation of a CoreValve system was associated with a 2.5-fold higher risk of PPM, which was confirmed in another systematic review 65 and in the recent report of the Society of Thoracic Surgeons Transcatheter Valve Therapy registry. 75 Baseline RBBB is probably the strongest, most consistent clinical predictor of PPM; it has been identified in more than half of the studies evaluating multivariable predictors of PPM (Table 2 and Table IV 146, 171 and from 5 to 6.7 mm with the Lotus valve. 61, 159 Values of 10% to 15% of valve oversizing have been associated with an increased risk of PPM with first-generation devices. 44, 46, 159, 171 Of particular interest concerning the postprocedural management of TAVR recipients are the predictors of delayed HAVB and HAVB recovery. The former was studied by Kagase et al in a series of 696 SAPIEN XT recipients including 48 patients with HAVB after TAVR. A total of 16 patients developed delayed HAVB (>24 hours after TAVR). In univariable analyses, the authors failed to identify meaningful associations between electrocardiographic, imaging, or procedural characteristics and the occurrence of delayed HAVB (A. Kagase, MD, unpublished data, 2016). In a larger series of 1064 patients (45% with selfexpandable valves), of whom 71 (6.7%) presented with delayed HAVB (defined as nonperiprocedural), Toggweiler et al 73 identified male sex and the presence of LBBB or RBBB after TAVR as independent predictors of delayed HAVB. Mouillet et al 177 also proposed a post-TAVR QRS duration cutoff of >128 milliseconds as a predictor of the evolution to delayed HAVB. Predictors of persistent HAVB ≥30 days after TAVR have also been studied by Kagase et al, who identified baseline RBBB as an independent risk factor (A. Kagase, MD, unpublished data, 2016), whereas baseline RBBB, PR interval duration before and after TAVR, PR interval change (>28 milliseconds) within 3 days of TAVR, and porcelain aorta have been highlighted as independent predictors of pacemaker dependency at 1 year after TAVR. 150 pre and post-TAVR electrophysiological studies in a series of 75 consecutive pacemaker-free TAVR recipients. A total of 30 patients developed new-onset LBBB, whereas 14 patients presented HAVB. The δ-HV interval (ie, HV interval after TAVR minus the HV interval before TAVR) was the only independent predictor of HAVB in the study population and the subgroup of patients with new LBBB, with an optimal cutoff of ≥13 milliseconds. When results of the pre-TAVR electrophysiological study were excluded from the analysis, the only predictor of HAVB was the delta QRS duration (ie, QRS duration after TAVR minus QRS duration before TAVR) with an optimal cutoff of 38 milliseconds. In the subgroup of patients with new-onset LBBB, when data from the pre-TAVR electrophysiological study were excluded, the only predictor of HAVB was the HV interval after TAVR, with an optimal cutoff of ≥65 milliseconds (sensitivity and specificity of 80.0% and 77.8%, respectively). 71 However, PPM was associated with a trend toward lower 1-year cardiac mortality (risk ratio, 0.77, 95% CI, 0.58-1.01; P=0.06), which may be explained by a reduction in sudden cardiac/unknown death, as previously suggested by Urena et al 39 in a multicenter registry of 1556 patients. Nonetheless, this metaanalysis did not include the latest report from the Society of Thoracic Surgeons Transcatheter Valve Therapy registry encompassing 9785 TAVR recipients that demonstrated an increased risk in 1-year overall mortality among patients who had PPM after TAVR (adjusted hazard-ratio, 1.31; 95% CI, 1.09-1.58; P=0.003; Figure 4) . 75 The poorer evolution of left ventricular ejection fraction among TAVR recipients receiving PPM may also explain such an observation. 39, 49, 52 Therefore, similar to LBBB, the association of PPM with midterm mortality remains controversial, which may reflect differences in PPM indications, pacemaker dependency, and ventricular pacing rates across studies. Moreover, current TAVR recipients are usually elderly patients with numerous noncardiac comorbidities influencing life expectancy. Therefore, the deleterious effects of long-term right ventricular pacing demonstrated in other settings, 179 may not be readily apparent in the sicker TAVR population with a reduced life expectancy that may limit the appearance of right ventricular pacing-induced left ventricular dysfunction with subsequent clinically apparent heart failure. Indeed, Watanabe et al 78 recently demonstrated an increased midterm mortality (>1 year post-TAVR) among patients with baseline RBBB undergoing PPM, a subset of patients likely to exhibit high rates of ventricular pacing 68, 149 (A. Kagase, MD, unpublished data, 2016), supporting the hypothesis that, among TAVR recipients, long-term pacing has detrimental effects, which are expressed at primarily midterm to long-term followup. 78 Further studies with longer follow-up and data on ventricular pacing rates are needed to confirm the negative association of PPM with mortality and to elucidate its underlying mechanisms.
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Clinical Association of PPM With Midterm Mortality After TAVR
MANAGEMENT OF CONDUCTION DISTURBANCES AFTER TAVR
Based on the available evidence, Figure 5 summarizes our proposal for the management of post-TAVR conduction disturbances. The proposed recommendations are based on observational studies, most of them retrospective in nature. To date, no randomized data are available in this field yet. Therefore, any recommendation for the management of conduction disturbances after TAVR should be seen as a suggestion and interpreted with caution. In addition to the cutoffs suggested in Figure 5 , particular attention should be paid to the evolution of ECG after TAVR for clinical decision making among TAVR recipients. Thus, a stable ECG for at least 48 hours demonstrates good negative predictive value for delayed HAVB. 
Preprocedural Electrocardiographic Monitoring
Up to 30% of patients who will eventually require PPM after TAVR exhibit episodes of HAVB or severe bradycardia diagnosed by 24-hour continuous electrocardiographic monitoring before TAVR, suggesting that the inclusion of a preprocedural period of electrocardiographic monitoring in the TAVR workflow may help to identify patients with conduction abnormalities that are not expected to resolve and could lead to an overall reduction in length of hospital stay. 28 Moreover, the presence of preexisting conduction disturbances, particularly RBBB, should probably drive the decision about transcatheter valve type. Considering the very high rate of HAVB after TAVR in those patients with RBBB receiving some types of transcatheter heart valves, 180 the use of valves with a lower risk of HAVB (eg, balloonexpandable valve or a self-expandable valve with a low risk of conduction disturbances) should probably be prioritized in these patients.
Electrocardiographic Monitoring After TAVR
Regardless of the occurrence of conduction disturbances, maintaining continuous telemetry during the hospi-talization period appears to be a simple and inexpensive measure for detecting bradyarrythmias and tachyarrythmias such as new-onset atrial fibrillation, which may increase the risk of potentially preventable thromboembolic events. 181, 182 The telemetry can be carried out in a conventional ward unless hospitalization in an intensive care unit is clinically indicated for other reasons.
Management of New-Onset LBBB
The management of new-onset LBBB after TAVR remains highly controversial considering the current lack of specific guidelines ( Figure 5A ). 144 The presence of new-onset persistent LBBB should prevent early discharge (within 24-48 hours after TAVR), and continuous electrocardiographic monitoring for at least 48 to 72 hours seems appropiate in these cases because of the increased risk of early progression to HAVB. 40, 47, 73, 75, 145, 148 For these reasons, keeping the temporary pacemaker with intensive care monitoring for 24 hours seems reasonable in these cases.
The progression of LBBB to HAVB should trigger the indication for PPM. However, LBBB will persist in most patients with no further changes (progression or regression) during the hospitalization period. 40, 41, 47, 50 In these cases, we suggest a careful evaluation of the ECG before hospital discharge. No specific measures have been proven effective for the management of these patients. Among others, the exact role of electrophysiological studies and implantable loop recorders in such cases remains unclear. (Table VI in the online-only Data Supplement), will likely shed more light on the natural history of conduction disturbances after TAVR. Meanwhile, and considering the higher risk of HAVB within the months after the procedure in patients with new-onset persistent LBBB, 40, 41, 71, 74 some remote monitoring (implantable loop recorder or 24-to 48-hour electrocardiographic monitoring at 30-day follow-up) may be advisable. This would also apply to those patients with LBBB and first-degree AVB, for whom an electrophysiological study or even PPM may be an option. 178, 183 However, the level of evidence for any of these measures remains low.
Particular attention should be paid to those patients with new-onset LBBB and a prolonged QRS duration (particularly >160 milliseconds), which has been associated with an increased risk of overall mortality and sudden cardiac death. 30, 35, 40, 41, 50 Thus, we think that this subgroup may have a reasonable indication for PPM. Other prophylactic indications for PPM in the context of new-onset LBBB lack evidence and may lead to an excessive and inappropriate number of PPM. However, further studies are warranted. 144 This contrasts with the observation that ≈50% of patients requiring PPM after TAVR receive this therapy within the 3 days after the procedure. 75 As previously discussed, such a conservative strategy is supported by observations from studies showing the transiency of HAVB in a sizeable proportion of patients and the increased risk of impaired left ventricular remodeling, repeat hospitalization for heart failure, and perhaps ultimately an increased risk of late mortality in pacemaker recipients. 75, 184 Nonetheless, a prolonged observation period often implies bedrest with the use of a temporary pacemaker and its inherent risks (thromboembolism, cardiac perforation). Thus, the safety, efficacy, and cost-effectiveness and the impact on functional recovery among aging patients after such a strategy remain largely unknown. Furthermore, it should be highlighted that this watchful period competes with the current trends toward shortened length of stay and even sometimes pacemaker reimbursement patterns. Indeed, some teams recently demonstrated that performing TAVR without intensive care unit admission and adopting a strategy of early discharge was feasible and did not result in an increased risk of rehospitalization or sudden cardiac death, 143, 185 suggesting that 24 hours of electrocardiographic monitoring may be sufficient in selected patients. Moreover, performing PPM the same day as TAVR may be a safe option, allowing rapid patient mobilization. 186 Therefore, we think that an observation period of 24 to 48 hours after the HAVB episode appears to be a reasonable compromise, especially in case of intraprocedural HAVB, which is less likely to recover >24 hours after its onset ( Figure 5B) . A more aggressive strategy of very early PPM (eg, at the time of the procedure), which may be appealing to reduce costs at the short term, would probably be futile in a significant proportion of patients with conduction disturbances that would eventually recover, further jeopardizing the midterm to long-term cost-effectiveness of TAVR. 187 The potential complications associated with PPM should also be taken into account. A recent prospective study demonstrated rates of 12.4% and 9.2% of short-and long-term complications after Figure 5 Continued. hospitalization in the intensive care unit (ICU) is clinically indicated for other reasons. The recommendation of continuous monitoring until discharge is for detecting not only bradyarrythmias but also tachyarrythmias such as new-onset atrial fibrillation, which may increase the risk of potentially preventable thromboembolic events. AVB indicates atrioventricular block; EPS, electrophysiological study; ILR, implantable loop recorder; and PPM, permanent pacemaker implantation.
Management of HAVB
PPM, respectively. 188 Lead-related complications occurred in 5.5% of patients, whereas 2.2% of patients had pneumothorax within 2 months of PPM. After lead complications, pocket hematoma was the most frequent complication, affecting 2.9% of patients overall. Indeed, dual antiplatelet therapy, a common antithrombotic strategy after TAVR, is associated with a 4-fold hazard of bleeding during the perioperative period, 189 suggesting that TAVR recipients might be at higher risk of complications after PPM. Therefore, conduction disturbances should be considered when antithrombotic therapies are prescribed after TAVR. Whenever possible, introduction of clopidogrel or oral anticoagulation should be postponed until PPM has been performed or deemed unnecessary.
Last, patients with transient HAVB regressing toward new-onset persistent LBBB should be managed as previously discussed ( Figure 5A ).
Choice of Pacemaker
Algorithms allowing the preservation of spontaneous atrioventricular conduction should be used in patients with paroxysmal HAVB to minimize long-term right ventricular pacing. In addition, resynchronization therapy should be considered in patients with HAVB, a sufficient life expectancy, a high (predictable >40%) percentage of ventricular pacing, and reduced left ventricular ejection fraction (<50%). 179, 190 Finally, some reports have shown the beneficial effects of resynchronization therapy in patients with a low left ventricular ejection fraction and persistent LBBB after TAVR. 191, 192 Resynchronization therapy may be reasonable among patients with preexisting left ventricular dysfunction and new-onset LBBB persisting at 30 days after TAVR, which might put these patients at higher mortality and morbidity risk. Currently, there are no data on the potential benefits of leadless pacemaker among TAVR recipients. Future studies should aim at defining predictors of low pacing burden, which might help delineate the optimal indication of these devices after TAVR.
CONCLUSIONS
A summary of what is known and what we need to know about conduction disturbances post-TAVR is shown in Table 3 .
Conduction disturbances remain a common complication of TAVR that may impair patients' prognosis. This complication is associated with left ventricular dyssynchrony, resulting in a poorer left ventricular function recovery and a higher rate of repeat hospitalization. New-onset LBBB after TAVR is associated with an increased risk of HAVB and sudden cardiac death that may be mitigated by PPM within 30 days after TAVR. However, PPM may also have a deleterious effect on left ventricular ejection fraction and increase the risk of heart failure at the midterm to long-term follow-up. The main risk factors of conduction disturbances include the presence of baseline RBBB, the use of some self-expanding valve systems, and the depth of prosthesis implantation within the LVOT. The use of newer-generation transcatheter valve devices does not seem to reduce the risk of conduction disturbances. Although the selection of the most appropriate device is influenced by numerous factors, including the degree Conduction disturbances (LBBB and HAVB requiring pacemaker implantation) are the most frequent complication of TAVR.
The optimal timing for temporary pacing and PPM (eg, minimal watchful period) in the presence of HAVB after TAVR.
The main factors determining the occurrence of conduction disturbances after TAVR are a low (more ventricular) transcatheter valve placement, the use of some self-expandable and mechanically expanded valves, and the presence of RBBB before the procedure. Most newer-generation transcatheter valves failed to reduce the incidence of conduction disturbances after TAVR.
The factors determining early and late progression/regression of conduction disturbances after TAVR.
Most conduction disturbances occur during the TAVR procedure or within hours after the procedure. A significant proportion of conduction disturbances (especially LBBB) will be transient, particularly with the use of balloon-expandable valves.
The midterm and long-term clinical impact of transient HAVB according to its timing of occurrence (during the procedure vs after the procedure).
Persistent LBBB at hospital discharge is associated with a negative effect on left ventricular function and a higher risk of HAVB requiring PPM at follow-up.
The clinical impact (mortality, heart failure) of LBBB after TAVR on midterm and long-term clinical outcomes (controversial results to date).
PPM after TAVR is not associated with an increased cardiac mortality rate at 1-y follow-up.
The long-term clinical impact of PPM after TAVR.
Role of "prophylactic" PPM in some cases of LBBB after TAVR (eg, those with larger QRS, first-degree AVB).
Role of resynchronization therapy in patients with reduced ventricular function and new persistent LBBB after TAVR.
AVB indicates atrioventricular block; HAVB, high-degree atrioventricular block; LBBB, left bundle-branch block; PPM, permanent pacemaker implantation; RBBB, right bundle-branch block; and TAVR, transcatheter aortic valve replacement. of native valve calcification or the risk of coronary obstruction, current data suggest that the use of a balloon-expandable valve or a self-expandable valve with a lower risk of conduction disturbances should be considered in patients at high risk of PPM (eg, those with RBBB at baseline). Limiting the indications of PPM to those strictly recommended in guidelines also reduces the need for PPM, and the risks and benefits of implementing a more prolonged period of electrocardiographic monitoring in the TAVR workflow need to be adequately assessed in prospective studies. Moreover, further studies are needed to better elucidate the factors associated with the development and recovery of conduction disturbances after TAVR, the optimal timing of PPM, and the management of the challenging group of patients with new-onset LBBB. 
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